KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer
Yingxi Zhao(Shenyang Pharmaceutical University), Lihui Wang(Shenyang Pharmaceutical University)
Cited by 4
Related Papers
Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity
|Cell Death and Disease|2017|134
An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer
|Molecular Cancer|2022|62
<p>LINC00565 promotes proliferation and inhibits apoptosis of gastric cancer by targeting miR-665/AKT3 axis</p>
|OncoTargets and Therapy|2019|25